Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.

Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

Abstract: The invention relates to a compound of formula (I) Wherein: B is adenine, guanine or hypoxanthine Z is hydrogen or a negative charge R is —[CH2CH(R1)—O]n—R2, —CH2CH2X, in which R1 is hydrogen or (C1-C6) alkyl R2 is hydrogen or (C1-C6) alkyl n is a number from 1 to 6 X is OH, F, NR3R4 R3 and R4 are independently from each other hydrogen or (C1-C6) alkyl and to methods of enzymatically treating these compounds with biocatalysts having cyclic phosphodiesterase activity.

Abstract: The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

Abstract: The invention pertains to the field of recombinant DNA technology and concerns a method for the production of a protein heterologous to yeast in a homogenous form with the aid of Saccharomyces cerevisiae strain HT393 or a derivative thereof carrying a hybrid vector containing the genes for said protein.

Abstract: Process for the production of alkali salts of clavulanic acid of formula ##STR1## by conversion of clavulanic acid into a pharmaceutically acceptable salt of clavulanic acid which is characterised in that the conversion is carried out in n-butanol or iso-butanol (2-methyl-1-propanol) as a solvent; and a potassium salt of clavulanic acid containing n-butanol or iso-butanol.

Abstract: A capsule dosage form containing solid form of terazosin in a solid carrier is disclosed. The capsule dosage form is stable under accelerated stability conditions and therapeutically equivalent to known liquid-filled terazosin capsules.

Abstract: A process for the production of a crystalline salt of amoxicillin utilizing ethanol as a solvent, and crystallizing the salt of amoxicillin in the presence of a salifying compound.

Abstract: Compounds of formulae I: (DIP)IrX.sub.q Y.sub.r (Z), Ia: (DIP)IrX.sub.s Y.sub.t (Z).sub.2 and Ib: (DIP)Ir(Z).sub.3 or mixtures of at least two of those compounds, wherein DIP is a ditertiary diphosphine, the two phosphine groups of which are bonded to a C.sub.2 -, C.sub.3 - or C.sub.4 -carbon chain, with the result that the diphosphine forms a 5- to 7-membered ring together with the Ir atom, X is Cl, Br or I, Y is a hydrogen atom, q and r are 0, 1 or 2 and the sum of q+r is 2, s and t are 0 or 1 and the sum of s+t is 1, and Z is the anion of an organic oxy acid that contains a group C(.dbd.O), S(.dbd.O)O or P(.dbd.O)O in the anion. The compounds are excellent catalysts for the hydrogenation of imines, especially for the enantioselective hydrogenation of prochiral imines.

Abstract: A process for the silylation of 6-aminopenicillanic acid or 7-amino-desacetoxy-cephalosporanic acid by silylation in certain carboxylic acid esters and its use in the production of 6-alpha-aminoacyl-penicillins and 7-alpha-aminoacyl-desacetoxy-cephalosporins.

Abstract: The invention relates to a process for the condensation of aldehydes or ketones with C--H acidic compounds (in particular Knoevenagel reaction) in the presence of at least one molecular sieve in the form of a zeolite or sheet silicate and one alkali carbonate, alkaline earth carbonate or ammonium carbonate as catalyst system. The products obtained are important intermediates or end products for the perfume industry.

Abstract: The invention relates to a process for detecting luminescence with a planar dielectric optical sensor platform consisting of a transparent substrate (a) to which a thin transparent waveguiding layer (b) is applied, which sensor platform is provided with a grating for the input-coupling of the excitation light and the refractive index of said substrate (a) is lower than the refractive index of the waveguiding layer (b), by bringing a liquid sample into contact with the layer (b), and measuring the luminescence produced by substances having luminescence properties in the sample, or by substances having luminescence properties immobilized on the layer (b), optoelectronically. The invention also relates to the use of the process in quantitative affinity sensing and to the use thereof for the quantitative determination of luminescent constituents in optically turbid solutions.

Abstract: A capsule dosage form containing solid form of terazosin in a solid carrier is disclosed. The capsule dosage form is stable under accelerated stability conditions and therapeutically equivalent to known liquid-filled terazosin capsules.

Abstract: Disclosed are dyes having the formula ##STR1## in which R.sub.1 is C.sub.1 -C.sub.4 alkoxy or chlorine,R.sub.2 is C.sub.1 -C.sub.4 alkyl,R.sub.3 is C.sub.1 -C.sub.4 alkyl,R.sub.4 is C.sub.1 -C.sub.4 alkyl,R.sub.5 is hydroxyethyl or hydroxypropyl, andAn.sup..crclbar. is an anion, in which R.sub.3 and R.sub.4 are not both ethyl at the same time, compositions containing the dyes and methods of using and preparing the dyes. The dyes are especially useful for dyeing polyacrylonitrile.

Abstract: The invention relates to a compound of formula (I), wherein R.sub.1 is C.sub.1 -C.sub.8 alkyl, phenyl or phenyl substituted by from 1 to 3 C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy substituents; R.sub.2 and R.sub.3 are each independently of the other hydrogen or C.sub.1 -C.sub.12 alkyl; and Hal is F, Cl, Br or I. Compounds of formula (I) are valuable intermediates for compounds of formula (III) which are also a subject of this invention, wherein R.sub.1, R.sub.2, R.sub.3 and Hal are as defined above; R.sub.10 and R.sub.11 are identical or different and are C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.12 cycloalkyl, phenyl, C.sub.5 -C.sub.12 cycloalkyl substituted by C.sub.1 -C.sub.4 alkyl or by C.sub.1 -C.sub.4 alkoxy, or phenyl substituted by from one to three C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --SiR.sub.4 R.sub.5 R.sub.6, halogen, --SO.sub.3 M, --CO.sub.2 M, --PO.sub.3 M, --NR.sub.7 R.sub.8, --?.sup.+ NR.sub.7 R.sub.8 R.sub.9 !X.sup.- or C.sub.1 -C.sub.